Clinical Trials Directory

Trials / Completed

CompletedNCT01112449

Influence of Selenium on Prostate Cancer Related Biomarkers

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
130 (actual)
Sponsor
Milton S. Hershey Medical Center · Academic / Other
Sex
Male
Age
20 Years – 79 Years
Healthy volunteers
Accepted

Summary

Penn State Milton S. Hershey Medical Center researchers are trying to compare the effects of two different forms of selenium (selenium yeast and selenomethionine) on blood selenium levels and biomarkers of oxidative stress as primary endpoints. One in six men are at risk of getting prostate cancer in their lifetime. Participants will be asked to take over-the-counter selenium yeast supplements and selenomethionine or a placebo for nine out of twelve months.

Detailed description

We will conduct a double-blind, randomized, placebo-controlled clinical study of selenium supplementation in the form of L-selenomethionine (SM)(200 µg/day) and selenium-enriched yeast (SY) (200 µg/day and 285 µg/day) for 9 months; the 285 µg/day SY is selected to deliver an equivalent selenium as in 200 µg/day SM to healthy men. The variability of SM in SY that will be used here is less than 3% and it accounts for 70.5% of the SM content in SY. As primary endpoints, we will determine the effects of these two forms of selenium on plasma levels of selenium and its metabolites as well as biomarkers of oxidative stress at several time points. As a secondary endpoint, the effect of these two forms of selenium on plasma PSA levels will be examined.

Conditions

Interventions

TypeNameDescription
OTHERPlacebono active medication
DIETARY_SUPPLEMENTselenomethionine200 µg/day of selenomethionine (SM)
DIETARY_SUPPLEMENTlow dose selenized-yeast200 µg/day of SY
DIETARY_SUPPLEMENThigh dose selenized-yeast285 µg/day of SY

Timeline

Start date
2008-05-01
Primary completion
2012-07-01
Completion
2014-05-01
First posted
2010-04-28
Last updated
2015-07-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01112449. Inclusion in this directory is not an endorsement.